Ligand validation:5AFN

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5AFN designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5AFN_NAG_A_301	62%	38%	0.09	0.891	0.62	1.76	-	4	1	0	93%	0.9333
5AFN_NAG_E_301	61%	35%	0.086	0.884	0.87	1.67	1	4	2	0	93%	0.9333
5AFN_NAG_C_301	55%	49%	0.101	0.88	0.58	1.37	-	3	4	0	93%	0.9333
5AFN_NAG_D_301	53%	37%	0.1	0.87	0.65	1.77	-	3	3	0	93%	0.9333
5AFN_NAG_B_301	49%	55%	0.099	0.854	0.64	1.09	-	2	3	0	93%	0.9333
5AFN_NAG_A_302	39%	30%	0.126	0.843	0.73	2.02	-	2	0	0	93%	0.9333
5AFN_NAG_B_302	25%	66%	0.106	0.752	0.46	0.85	-	-	1	0	93%	0.9333
5AFN_NAG_C_302	13%	63%	0.127	0.673	0.47	0.94	-	1	1	0	93%	0.9333
5AFN_NAG_E_302	9%	45%	0.141	0.641	0.49	1.61	-	2	2	0	93%	0.9333
5AFN_NAG_D_302	9%	64%	0.126	0.623	0.42	0.93	-	1	1	0	93%	0.9333
5AFM_NAG_C_301	68%	24%	0.105	0.927	1.4	1.68	3	5	1	0	93%	0.9333
4HQP_NAG_B_803	28%	66%	0.241	0.893	0.69	0.63	-	-	1	0	100%	0.9333
3SQ9_NAG_C_901	15%	61%	0.11	0.671	0.98	0.54	1	-	3	0	100%	0.9333
3SQ6_NAG_H_901	14%	53%	0.142	0.685	0.95	0.86	1	1	2	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.